



Quality For All

**Tenth of Ramadan for Pharmaceutical Industries
and Diagnostic Reagents (Rameda) S.A.E**

PRESS RELEASE

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Commences Manufacturing of Antiviral COVID-19 Treatment, Molnupiravir Rameda

17 January 2022 | Cairo, Egypt

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E., (RMDA.CA on the EGX), a leading Egyptian pharmaceutical company, announces that the company has begun the commercial production of Molupiravir Rameda, the generic form of the oral antiviral medicine developed by Merck and approved for the treatment of COVID-19 in adults, after receiving the necessary authorizations from the Egyptian Drug Authority (EDA). Merck's developed version has received emergency use authorization from the US Food and Drug Administration (USFDA) and standard authorization from the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for severe COVID-19 progression.

The company is coordinating its production plans with the EDA and Egypt's Ministry of Health with the aim of ensuring that market demand for the treatment is met fully and in a timely manner. Rameda will release the antiviral into the market before the end of Q1-2022 at a retail price of EGP 625 per 40 capsules and with an initial dose of 200 milligrams, the strength approved by both the USFDA and MHRA, and stands ready to launch the medicine at increased strengths in due course.

"The production of Molnupiravir Rameda marks yet another important step in Rameda's support of Egypt's response to the COVID-19 pandemic," said Dr Amr Morsy, CEO of Rameda. "As an oral treatment, Molnupiravir Rameda offers a significant new addition to the arsenal of medicines we've deployed against the pandemic so far, which have contributed 12% to our overall top line in 9M21. Molnupiravir Rameda is the latest addition to our antivirals portfolio and will allow the company to capture a greater share of the fast-growing antivirals market. According to IQVIA, as of November 2021 strictly private sales of antivirals reached c. EGP 230 million during the eleven-month period. This is in addition to the potential and sizable sales generated in the tender and export markets."

"Subject to supportive medical evidence, we expect Molnupiravir Rameda to potentially generate an upside in the coming year, and we will move with urgency and determination to bring the treatment to patients across the country as rapidly as possible," Morsy added.

Rameda's has received quality assurance certification from the EDA for the production of Molnupiravir Rameda and is manufacturing the antiviral according to approved technical handling procedures and good manufacturing practice, ensuring that treatments are consistently produced and controlled according to quality standards.

-Ends-

Investor Relations Contact:

Yasmine Negm
Rameda's Head of Institutional Investor Relations & Corporate Governance
Email: yasmine.negm@rameda.com
Mobile: +20(0) 1228505050



Quality For All

About Rameda

Established in 1986, Rameda (RMDA.CA on EGX) is a leading Egyptian pharmaceutical company led by a team of professionals with extensive multinational experience. The company develops and produces a wide range of branded generic pharmaceuticals, nutraceuticals, food supplements and veterinary products. Rameda combines global standards with local insights and a customer-centric approach. It has developed a broad portfolio of products across multiple therapeutic areas by successfully leveraging its strong product portfolio with its accretive product acquisitions to become one of the fastest-growing pharmaceutical players in Egypt. The company produces its wide range of dosage forms at its three manufacturing facilities located at its industrial complex in Cairo's Sixth of October Industrial Zone.

Forward-Looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "anticipates", "assumes", "believes", "could", "estimates", "expects", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would", or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding our business and management, our future growth or profitability and general economic and regulatory conditions and other matters affecting us.

Forward-looking statements reflect our management's ("Management") current views of future events, are based on Management's assumptions, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause our actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements. Our business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate, or prediction to become inaccurate. These risks include fluctuations in the prices of raw materials or employee costs required by our operations, its ability to retain the services of certain key employees, its ability to compete successfully, changes in political, social, legal, or economic conditions in Egypt, worldwide economic trends, the impact of war and terrorist activity, inflation, interest rate and exchange rate fluctuations, and Management's ability to timely and accurately identify future risks to our business and manage the risks mentioned above.

Certain figures contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly to the total figure given.